ArticleLipids2003
Tissue deposition of n-3 FA pathway intermediates in the synthesis of DHA in rainbow trout (Oncorhynchus mykiss).
Article in Lipids, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 11 citations in OpenAlex.
- Fads2b Plays a Dominant Role in ∆6/∆5 Desaturation Activities Compared with Fads2a in Common Carp (International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tissue distribution of newly synthesized 22:6n-3 and intermediate PUFA was examined in rainbow trout to further our understanding of the metabolism of this EFA in fish. Rainbow trout were fed a pulse of deuterated linolenic acid (D5-17,17,18,18,18-18:3n-3), and the tissue distribution of deuterated anabolites was determined at intervals up to 35 d post-dose by GC-negative chemical ionization MS of the pentafluorobenzyl derivatives. D5-22:6n-3 was the major deuterated FA in liver and cecal mucosa 2 and 5 d post-dose. All the n-3 FA pathway intermediates were found in liver, cecal mucosa, and blood including D5-24:5n-3 and D5-24:6n-3. Brain and eyes also contained the full suite of intermediate deuterated FA, but with a different profile from liver when analyzed over a longer time course up to 35 d. D5-20:5n-3 was the major component in brain up to 7 d, after which D5-22:6n-3 became predominant, but D5-22:5n-3 constituted ca. 20% of FA throughout the time period. The pattern in eyes was similar but less pronounced. In visceral adipose tissue there was a much greater accumulation of the initial substrate, D5-18:3n-3, with D5-18:4n-3 and D5-22:6n-3 the predominant deuterated FA at all time points. There was a similar though less pronounced trend in eye socket adipose tissue. The C24 PUFA were not detected in visceral fat and barely detected in eye socket fat. The results show that the kinetics of accumulation and depletion of the various n-3 PUFA differ between tissues. The presence of pathway intermediate FA provides evidence that liver and ceca possess the full metabolic pathway for synthesis of 22:6n-3, whereas brain and eyes are less active, with an accumulation of pentaene intermediate FA, and adipose tissue is inactive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.